CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 99 enrolled
Drug / intervention
HPV vaccine for strains -6, -11, -16, and -18biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00710593
NCT00710593Phase 2Completed
CompareCT.gov

Immunogenicity, Safety, Tolerability, and Behavioral Consequences of an HPV-6, -11, -16, -18 Vaccine in HIV-Infected Young Women

University of North Carolina, Chapel Hill·interventional·Posted Jul 4, 2008·Updated Jul 2, 2017

In Brief

A Phase 2 clinical trial evaluating HPV vaccine for strains -6, -11, -16, and -18 for HIV Infection. Completed, enrolled 99 participants across 14 sites in 2 countries.

Detailed Summary

The purpose of this study is to evaluate the immunogenicity, safety, tolerability, and behavioral impact of an HPV-6, -11, -16, -18 vaccine in HIV-infected young women.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infection
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 4, 2008
Enrollment StartFeb 1, 2008
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 18.0 years ago

Interventions

HPV vaccine for strains -6, -11, -16, and -18biological

All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).